Source:http://linkedlifedata.com/resource/pubmed/id/11807227
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
Pt 2
|
pubmed:dateCreated |
2002-1-24
|
pubmed:abstractText |
The enterovirus 2B protein contains a putative amphipathic alpha-helix that includes three positively charged and one negatively charged residue. Previously, we observed that replacement of the glutamic acid-40 residue with a lysine residue (mutation 2B-E[40]K) in the amphipathic alpha-helix of the coxsackie B3 virus 2B protein resulted in a quasi-infectious phenotype. On one occasion, however, transfection of 2B-E[40]K RNA transcripts gave rise to a virus stock in which the mutation was retained. This study was aimed at elucidating the molecular mechanism underlying this observation. Sequence analysis of the viral RNA provided no evidence for a second-site suppression mutation that rescued the defect of the 2B-E[40]K mutation in cis. Therefore, the possibility was considered that the defect caused by the 2B-E[40]K mutation was complemented in trans by viable revertants that had emerged in the virus population. The transfection-derived virus stock indeed contained a small fraction of (pseudo)revertant viruses, carrying the original glutamic acid-40, threonine-40 or asparagine-40, rather than the introduced lysine-40. Consistent with the idea that the 2B-E[40]K virus is unable to grow without the aid of trans-acting wild-type(-like) proteins, only the (pseudo)revertant viruses were able to produce individual plaques. Further support for the idea of trans-rescue was obtained using a genetic complementation assay, which revealed the occurrence of a low level of trans-complementation of the 2B-E[40]K mutation by wild-type virus. This is the first report that provides evidence that a genetic defect in the enterovirus 2B protein can be complemented in trans.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0022-1317
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
341-50
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11807227-Animals,
pubmed-meshheading:11807227-Cell Line,
pubmed-meshheading:11807227-Enterovirus B, Human,
pubmed-meshheading:11807227-Enterovirus Infections,
pubmed-meshheading:11807227-Genetic Complementation Test,
pubmed-meshheading:11807227-Humans,
pubmed-meshheading:11807227-Mutation,
pubmed-meshheading:11807227-RNA, Viral,
pubmed-meshheading:11807227-Sequence Analysis, DNA,
pubmed-meshheading:11807227-Transfection,
pubmed-meshheading:11807227-Viral Plaque Assay,
pubmed-meshheading:11807227-Viral Proteins
|
pubmed:year |
2002
|
pubmed:articleTitle |
Trans-complementation of a genetic defect in the coxsackie B3 virus 2B protein.
|
pubmed:affiliation |
Department of Medical Microbiology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands. f.vankuppeveld@ncmls.kun.nl
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|